Description:

Crizalk 250 (Crizotinib) is a targeted anticancer medication used to treat specific types of non-small cell lung cancer (NSCLC). It is an oral tyrosine kinase inhibitor that works by blocking abnormal proteins that drive cancer cell growth, particularly in tumors with ALK (anaplastic lymphoma kinase) or ROS1 gene rearrangements.

By inhibiting ALK and ROS1, Crizalk slows or stops the growth of cancer cells and helps to shrink tumors, offering an important treatment option for patients whose tumors are driven by these genetic mutations.

Uses / Indications:

• Treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC)
• Treatment of patients with ROS1-positive metastatic NSCLC

The presence of ALK or ROS1 gene alterations must be confirmed through approved testing before starting therapy.